Mediwing Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 14-12-2024
- Paid Up Capital ₹ 0.63 M
as on 14-12-2024
- Company Age 24 Year, 9 Months
- Last Filing with ROC 31 Mar 2016
- Open Charges ₹ 0.50 M
as on 14-12-2024
- Revenue -4.97%
(FY 2016)
- Profit 84.86%
(FY 2016)
- Ebitda 89.76%
(FY 2016)
- Net Worth -0.85%
(FY 2016)
- Total Assets -3.16%
(FY 2016)
About Mediwing Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2016. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.63 M.
The company currently has active open charges totaling ₹0.50 M.
Kanakamma Nair, Nair Murleedharan, and Joseph John serve as directors at the Company.
- CIN/LLPIN
U24231KL2000PTC013702
- Company No.
013702
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Feb 2000
- Date of AGM
30 Sep 2016
- Date of Balance Sheet
31 Mar 2016
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mediwing Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nair Murleedharan  | Managing Director | 30-Mar-2009 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kanakamma Nair | Additional Director | 30-Mar-2009 | Current |
| Joseph John | Additional Director | 19-Nov-2009 | Current |
Financial Performance and Corporate Structure Insights of Mediwing Pharmaceuticals.
Mediwing Pharmaceuticals Private Limited, for the financial year ended 2016, experienced Minor drop in revenue, with a 4.97% decrease. The company also saw a substantial improvement in profitability, with a 84.86% increase in profit. The company's net worth dipped by a decrease of 0.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mediwing Pharmaceuticals?
In 2016, Mediwing Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Northstone Builders And Developers Private LimitedActive 16 years 6 monthsNair Murleedharan is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab & Sind Bank Creation Date: 13 May 2003 | ₹0.25 M | Open |
The Dhanalakshmi Bank Limited Creation Date: 27 Oct 2000 | ₹0.25 M | Open |
How Many Employees Work at Mediwing Pharmaceuticals?
Unlock and access historical data on people associated with Mediwing Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mediwing Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mediwing Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
